<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following risk factors should", fill: "#4b3621"},
{source: "1: following risk factors should", target: "1: conjunction with", fill: "#4b3621"},
{source: "1: conjunction with", target: "1: Annual Report ", fill: "#4b3621"},
{source: "1: Annual Report ", target: "1: involve risks", fill: "#4b3621"},
{source: "1: involve risks", target: "1: uncertainties", fill: "#4b3621"},
{source: "1: following risk factors should", target: "4: strategy depends on", fill: "#b5651d"},
{source: "4: strategy depends on", target: "4: successfully commercialize", fill: "#b5651d"},
{source: "4: successfully commercialize", target: "4: broad range", fill: "#b5651d"},
{source: "4: broad range", target: "4: products based on mass spectrometry", fill: "#b5651d"},
{source: "4: products based on mass spectrometry", target: "4: technology", fill: "#b5651d"},
{source: "4: technology", target: "4: life science applications", fill: "#b5651d"},
{source: "4: strategy depends on", target: "12: intended life science customers", fill: "#004953"},
{source: "12: intended life science customers", target: "12: costeffective alternative", fill: "#004953"},
{source: "12: costeffective alternative", target: "12: technologies", fill: "#004953"},
{source: "12: technologies", target: "12: acquisition analysis", fill: "#004953"},
{source: "12: acquisition analysis", target: "12: management", fill: "#004953"},
{source: "12: intended life science customers", target: "22: recover significant development costs", fill: "#48d1cc"},
{source: "22: recover significant development costs", target: "22: product lines", fill: "#48d1cc"},
{source: "22: product lines", target: "22: operations", fill: "#48d1cc"},
{source: "22: operations", target: "22: financial condition may suffer", fill: "#48d1cc"},
{source: "22: recover significant development costs", target: "24: significant", fill: "#d2691e"},
{source: "24: significant", target: "24: revenues each year from", fill: "#d2691e"},
{source: "24: revenues each year from", target: "24: previous two years", fill: "#d2691e"},
{source: "24: significant", target: "32: technologies indirectly compete", fill: "#dea5a4"},
{source: "32: technologies indirectly compete", target: "32: funding with technologies", fill: "#dea5a4"},
{source: "32: funding with technologies", target: "32: products provided by", fill: "#dea5a4"},
{source: "32: products provided by", target: "32: affiliates", fill: "#dea5a4"},
{source: "32: affiliates", target: "32: Bruker BioSpin ", fill: "#dea5a4"},
{source: "32: Bruker BioSpin ", target: "32: competition", fill: "#dea5a4"},
{source: "32: technologies indirectly compete", target: "38: reliance on", fill: "#d2691e"},
{source: "38: reliance on", target: "38: suppliers could", fill: "#d2691e"},
{source: "38: suppliers could", target: "38: delays associated with", fill: "#d2691e"},
{source: "38: delays associated with", target: "38: redesigning", fill: "#d2691e"},
{source: "38: redesigning", target: "38: product due", fill: "#d2691e"},
{source: "38: product due", target: "38: inability", fill: "#d2691e"},
{source: "38: inability", target: "38: adequate supply", fill: "#d2691e"},
{source: "38: adequate supply", target: "38: components", fill: "#d2691e"},
{source: "38: components", target: "38: reduced control over pricing quality", fill: "#d2691e"},
{source: "38: reliance on", target: "262: market price", fill: "#ccf"},
{source: "262: market price", target: "262: common stock may fluctuate substantially", fill: "#ccf"},
{source: "262: common stock may fluctuate substantially", target: "262: various factors", fill: "#ccf"},
{source: "262: various factors", target: "262: quarterly fluctuations", fill: "#ccf"},
{source: "262: quarterly fluctuations", target: "262: operations as described", fill: "#ccf"},
{source: "262: operations as described", target: "262: successfully commercialize", fill: "#ccf"},
{source: "262: successfully commercialize", target: "262: technological innovations", fill: "#ccf"},
{source: "262: technological innovations", target: "262: new commercial products by us", fill: "#ccf"},
{source: "262: new commercial products by us", target: "262: competitors", fill: "#ccf"},
{source: "262: competitors", target: "262: development", fill: "#ccf"},
{source: "262: development", target: "262: proprietary rights", fill: "#ccf"},
{source: "262: proprietary rights", target: "262: which could affect", fill: "#ccf"},
{source: "262: which could affect", target: "262: potential growth", fill: "#ccf"},
{source: "262: potential growth", target: "262: relationships with", fill: "#ccf"},
{source: "262: relationships with", target: "262: market reaction", fill: "#ccf"},
{source: "262: market reaction", target: "262: expenses especially", fill: "#ccf"},
{source: "262: expenses especially", target: "262: by analysts", fill: "#ccf"},
{source: "262: by analysts", target: "262: volatility", fill: "#ccf"},
{source: "262: volatility", target: "262: uncertainty", fill: "#ccf"},
{source: "262: uncertainty", target: "262: capital markets", fill: "#ccf"},
{source: "262: capital markets", target: "262: key personnel", fill: "#ccf"},
{source: "262: key personnel", target: "262: accounting principles", fill: "#ccf"},
{source: "262: accounting principles", target: "262: trading volume", fill: "#ccf"},
{source: "262: trading volume", target: "262: fluctuation within", fill: "#ccf"},
{source: "262: fluctuation within", target: "262: life science", fill: "#ccf"},
{source: "262: life science", target: "262: common stock by existing stockholders particularly", fill: "#ccf"},
{source: "262: common stock by existing stockholders particularly", target: "262: institutional investors", fill: "#ccf"},
{source: "262: institutional investors", target: "262: political conditions", fill: "#ccf"},
{source: "262: market price", target: "START_HERE", fill: "#ccf"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_management">Risk management</a></td>
      <td>Risk management is the identification, evaluation, and prioritization of risks (defined in ISO 31000 as the effect of uncertainty on objectives) followed by coordinated and economical application of resources to minimize, monitor, and control the probability or impact of unfortunate events or to maximize the realization of opportunities.\nRisks can come from various sources including uncertainty in international markets, threats from project failures (at any phase in design, development, production, or sustaining of life-cycles), legal liabilities, credit risk, accidents, natural causes and disasters, deliberate attack from an adversary, or events of uncertain or unpredictable root-cause.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management">Management</a></td>
      <td>Management (or managing) is the administration of an organization, whether it is a business, a non-profit organization, or a government body. It is the art and science of managing resources of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agile_management">Agile management</a></td>
      <td>Agile management is the application of the principles of Agile software development to various management processes, particularly project management. Following the appearance of the Manifesto for Agile Software Development in 2001, Agile techniques started to spread into other areas of activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_management">Sport management</a></td>
      <td>Sport management is the field of business dealing with sports and recreation. Sports management involves any combination of skills that correspond with planning, organizing, directing, controlling, budgeting, leading, or evaluating of any organization or business within the sports field.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Project_management">Project management</a></td>
      <td>Project management is the process of leading the work of a team to achieve all project goals within the given constraints. This information is usually described in project documentation, created at the beginning of the development process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women_Management">Women Management</a></td>
      <td>Women Management is a modeling agency based in New York. Founded by Paul Rowland in 1988,  Women also has two sister agencies, Supreme Management and Women 360 Management, which is also part of the Women International Agency Chain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_management">Emergency management</a></td>
      <td>Emergency management, also called emergency response or disaster management, is the organization and management of the resources and responsibilities for dealing with all humanitarian aspects of emergencies (prevention, preparedness, response, mitigation, and recovery). The aim is to prevent and reduce the harmful effects of all hazards, including disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Affiliate_marketing">Affiliate marketing</a></td>
      <td>Affiliate marketing is a type of performance-based marketing in which a business rewards one or more affiliates for each visitor or customer brought by the affiliate's own marketing efforts.Affiliate marketing may overlap with other Internet marketing methods, including organic search engine optimization (SEO), paid search engine marketing (PPC – Pay Per Click), e-mail marketing, content marketing, and display advertising.Affiliate marketing is frequently overlooked by advertisers. While search engines, e-mail, and web site syndication capture much of the attention of online retailers, affiliate marketing carries a much lower profile.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BRUKER BIOSCIENCES CORP      ITEM 1A        RISK FACTORS       The <font color="blue">following risk factors should</font> be considered in <font color="blue">conjunction with</font> the     other information included in this <font color="blue">Annual Report </font>on Form 10-K This report     may include forward-looking statements that <font color="blue">involve risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>In addition to those <font color="blue">risk factors discussed elsewhere</font> in this report, we     identify the following risk factors, <font color="blue">which could</font> affect our actual results     and  cause  actual  results  to  differ  <font color="blue">materially</font>  from those in the     forward-looking statements</td>
    </tr>
    <tr>
      <td>If our <font color="blue">products fail</font> to achieve and <font color="blue">sustain sufficient <font color="blue">market <font color="blue">acceptance</font></font></font>     across their <font color="blue">broad intended range</font> of <font color="blue">applications</font>, we will not generate     expected revenue</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">strategy depends on</font> our ability to <font color="blue"><font color="blue">successfully</font> commercialize</font> a     <font color="blue">broad range</font> of <font color="blue">products <font color="blue">based on</font> mass <font color="blue">spectrometry</font></font> and X-ray <font color="blue">technology</font> for     use in a variety of <font color="blue">life science</font> <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Some of our products have     only recently been <font color="blue">commercially</font> launched and have achieved only limited     sales to date</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue"><font color="blue"><font color="blue">life science</font> products</font> depends</font>     on our obtaining continued and <font color="blue">expanding <font color="blue">market <font color="blue">acceptance</font></font></font> of our mass     <font color="blue">spectrometry</font> and X-ray tools by <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and proteomics     companies and academic and government research <font color="blue">laboratories</font>, among others,     across the wide range of <font color="blue">applications</font> <font color="blue">covered by</font> our <font color="blue">product offerings</font></td>
    </tr>
    <tr>
      <td>We     may  fail  to achieve or sustain substantial <font color="blue">market <font color="blue">acceptance</font></font> for our     <font color="blue">products across</font> the full range of our intended <font color="blue">life science</font> <font color="blue">applications</font> or     in one or more of our principal intended <font color="blue">life science</font> <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">failure <font color="blue">could decrease</font></font> our sales and revenue</td>
    </tr>
    <tr>
      <td>To succeed, we <font color="blue">must convince</font>     substantial numbers of <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies and other     <font color="blue">laboratories</font> to invest in <font color="blue">new systems</font> or replace their <font color="blue">existing techniques</font>     with mass <font color="blue">spectrometry</font> and X-ray <font color="blue">techniques employing</font> our systems</td>
    </tr>
    <tr>
      <td><font color="blue">Limited     </font><font color="blue">funding available</font> for <font color="blue">capital <font color="blue"><font color="blue">acquisition</font>s</font> by</font> our customers, as well as our     customers’ own internal purchasing approval policies, could hinder market     <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">intended <font color="blue">life science</font> customers</font> may</font> be     reluctant to make the substantial <font color="blue">capital investment <font color="blue">generally</font></font> needed to     acquire our products or to incur the training and other <font color="blue">costs involved with</font>     replacing their <font color="blue">existing systems with</font> our products</td>
    </tr>
    <tr>
      <td>We also may not be able     to convince our <font color="blue">intended <font color="blue">life science</font> customers</font> that our systems are an     attractive and cost-<font color="blue">effective</font> alternative to other <font color="blue">technologies</font> and systems     for the <font color="blue">acquisition</font>, analysis and <font color="blue">management</font> of molecular information</td>
    </tr>
    <tr>
      <td>Because of these and other factors, our <font color="blue">products may fail</font> to gain or sustain     <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       Our products compete in markets that are subject to <font color="blue">rapid <font color="blue">technological</font></font>     change, and most of our products are <font color="blue">based on</font> a range of mass <font color="blue">spectrometry</font>     and X-ray <font color="blue">technologies</font> one or more of <font color="blue">which could</font> be made <font color="blue">obsolete by new</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The  market for <font color="blue"><font color="blue">life science</font> <font color="blue">discovery</font> tools</font> is <font color="blue">characterized by rapid</font>     <font color="blue">technological</font>  change  and <font color="blue">frequent new product <font color="blue">introduction</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Rapidly     </font>changing <font color="blue">technology</font> could make some or all of our <font color="blue"><font color="blue">life science</font> <font color="blue">product lines</font></font>     <font color="blue">obsolete unless</font> we are able to <font color="blue"><font color="blue">continually</font> improve</font> our <font color="blue">existing products</font> and     develop <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">substantially</font> all of our <font color="blue"><font color="blue">life science</font> products</font>     are <font color="blue">based on</font> mass <font color="blue">spectrometry</font> and X-ray <font color="blue">technology</font>, we are <font color="blue">particularly</font>     vulnerable  to  any <font color="blue">technological</font> advances that would make <font color="blue">either mass</font>     <font color="blue">spectrometry</font> or X-ray <font color="blue">technologies</font> obsolete as the basis for <font color="blue">bioanalytical</font>     systems in any of our <font color="blue"><font color="blue">life science</font> markets</font></td>
    </tr>
    <tr>
      <td>To meet the evolving needs of     our customers, we <font color="blue">must rapidly</font> and <font color="blue"><font color="blue">continually</font> enhance</font> our current and     planned products and services and develop and introduce <font color="blue">new products</font> and     services</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">product lines</font> are <font color="blue">based on</font> complex <font color="blue">technologies</font>     which are subject to rapid change as new <font color="blue">technologies</font> are developed and     introduced in the marketplace</td>
    </tr>
    <tr>
      <td>We may have <font color="blue"><font color="blue">difficult</font>y</font> in keeping abreast of     the rapid changes <font color="blue">affecting each</font> of the <font color="blue">different markets</font> we serve or intend     to serve</td>
    </tr>
    <tr>
      <td>If we fail to develop and introduce products in a <font color="blue">timely manner</font> in     response to changing <font color="blue">technology</font>, market demands or the <font color="blue">requirements</font> of our     customers,  our  product  sales  may  decline, and we could experience     <font color="blue"><font color="blue">significant</font> losses</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">recover <font color="blue">significant</font> <font color="blue">development</font> costs</font> of one or more of     our products or <font color="blue">product lines</font>, our business, results of <font color="blue">operations</font> and     <font color="blue"><font color="blue">financial condition</font> may suffer</font></td>
    </tr>
    <tr>
      <td>We offer and plan to continue to offer a <font color="blue">broad product line</font> and incur and     expect to continue to incur substantial expenses for the <font color="blue">development</font> of new     products and <font color="blue">enhanced versions</font> of our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Our business model     calls for us to derive a <font color="blue">significant</font> portion of our <font color="blue">revenues each year from</font>     products that did not exist in the <font color="blue">previous two years</font></td>
    </tr>
    <tr>
      <td>However, we may     experience  <font color="blue"><font color="blue">difficult</font>ies</font>  which  may  delay  or prevent the successful     <font color="blue">development</font>,  <font color="blue">introduction</font>  and  marketing  of <font color="blue">new products</font> or product     <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>The speed of <font color="blue">technological</font> change in <font color="blue">life science</font> and other     related markets we <font color="blue">serve may prevent us from <font color="blue">successfully</font> marketing</font> some or     all of our products for the length of time required to recover their often     <font color="blue">significant</font> <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>If we fail to recover the <font color="blue">development</font> costs     of  one  or  more  products or <font color="blue">product lines</font>, our business, results of     <font color="blue">operations</font> and <font color="blue"><font color="blue">financial condition</font> could</font> be harmed</td>
    </tr>
    <tr>
      <td>We face substantial <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We face substantial <font color="blue">competition</font> and we expect that <font color="blue">competition</font> in all of our     <font color="blue">markets will increase further</font></td>
    </tr>
    <tr>
      <td>Currently, our principal <font color="blue">competition</font> comes     from established companies providing products using existing <font color="blue">technologies</font>,     including mass <font color="blue">spectrometry</font>, X-ray <font color="blue">technology</font>, NBC <font color="blue">detection</font> <font color="blue">technologies</font>     and other <font color="blue">technologies</font>, which perform many of the <font color="blue">same functions</font> for which     we market our products</td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies also may choose</font> to enter our field     in the future</td>
    </tr>
    <tr>
      <td>In addition, some of our <font color="blue">technologies</font> <font color="blue">indirectly</font> compete for     funding with <font color="blue">technologies</font> and <font color="blue">products provided by</font> some of our <font color="blue">affiliates</font>,     such as Bruker BioSpin; this <font color="blue">competition</font> creates the potential for actual or     perceived conflicts of interest</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">competitor</font>s</font> may</font> develop or market     products that are more <font color="blue">effective</font> or <font color="blue">commercially</font> attractive than our current     or <font color="blue">future products</font> or that may render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue"><font color="blue">competitor</font>s</font>  have  more  experience  in  the  <font color="blue">life science</font>s market and     <font color="blue">substantially</font>  greater financial, operational, marketing and technical     resources than we do <font color="blue">which could</font> give them a <font color="blue">competitive</font> edge in areas such     as research and <font color="blue">development</font>, production, marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Our     ability to <font color="blue">compete <font color="blue">successfully</font> will depend</font>, in part, on our ability to     develop <font color="blue"><font color="blue">proprietary</font> products</font> that reach the market in a <font color="blue">timely manner</font> and     are <font color="blue">technological</font>ly superior to, <font color="blue">less expensive than</font>, or more cost-<font color="blue">effective</font>     than, other <font color="blue">currently marketed products</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Our <font color="blue">operations</font> are <font color="blue">dependent upon</font> a limited number of suppliers and contract     <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently purchase <font color="blue">components</font> used</font> in our mass <font color="blue">spectrometry</font> and X-ray     systems  from a limited number of <font color="blue">outside suppliers</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> a     limited number of <font color="blue">suppliers could</font> result in time <font color="blue">delays <font color="blue">associated with</font></font>     <font color="blue">redesigning</font> a <font color="blue">product due</font> to an <font color="blue">inability</font> to obtain an <font color="blue">adequate supply</font> of     required <font color="blue">components</font> and reduced control over pricing, quality and timely     delivery</td>
    </tr>
    <tr>
      <td>Any of these factors could <font color="blue">adversely</font> affect our revenues and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>For example, we currently purchase key <font color="blue">components</font> used in our     mass <font color="blue">spectrometry</font> and X-ray <font color="blue">systems from certain suppliers</font></td>
    </tr>
    <tr>
      <td>In particular,     <font color="blue">Bruker AXS </font>obtains a <font color="blue">sophisticated</font> chip for use in its CCD <font color="blue">detectors from</font>     <font color="blue">Fairchild Imaging </font>which, to Bruker AXS’ knowledge, is the only source of a     chip of this size and quality</td>
    </tr>
    <tr>
      <td>The X-ray <font color="blue">microanalysis</font> business of Bruker     AXS, <font color="blue">which <font color="blue">manufacture</font>s</font> and <font color="blue">sells accessories</font> for electron <font color="blue">microscopes</font>, is     partially <font color="blue">dependent on</font> cooperation from larger <font color="blue"><font color="blue">manufacture</font>rs</font> of electron     <font color="blue">microscopes</font></td>
    </tr>
    <tr>
      <td>Additionally, Bruker Daltonics purchases a substantial portion     of its <font color="blue">magnets from</font> a <font color="blue">single supplier</font>, Varian/Magnex, and also obtains     certain key <font color="blue">components</font> for the <font color="blue">manufacture</font> of its <font color="blue">ion traps from</font> Agilent,     the sole supplier of these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Because of the scarcity of some     <font color="blue">components</font>, we may be unable to obtain an <font color="blue">adequate supply</font> of <font color="blue">components</font>, or     we may be required to <font color="blue">pay higher prices</font> or to purchase <font color="blue">components</font> of lesser     quality</td>
    </tr>
    <tr>
      <td>Any  delay  or  <font color="blue">interruption</font> in the supply of these or other     <font color="blue">components</font> could impair our ability to <font color="blue">manufacture</font> and deliver our products,     harm our reputation and cause a reduction in our revenues</td>
    </tr>
    <tr>
      <td>In addition, any     increase in the cost of the <font color="blue">components</font> that we use in our <font color="blue">products could</font>     make our products less <font color="blue">competitive</font> and decrease our gross margins</td>
    </tr>
    <tr>
      <td>We may     not be able to obtain <font color="blue">sufficient quantities</font> of required <font color="blue">components</font> on the     same or <font color="blue">substantially</font> the <font color="blue">same terms</font></td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">consolidations among</font> our     <font color="blue">suppliers could</font> result in <font color="blue"><font color="blue">additional</font> sole source suppliers</font> for us in the     future</td>
    </tr>
    <tr>
      <td>Our business could be harmed if our <font color="blue"><font color="blue">collaborations</font> fail</font> to advance our     product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Demand for our products will depend in part upon the extent to which our     <font color="blue">collaborations</font> with <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and proteomics companies     are successful in developing, or helping us to develop, <font color="blue">new products</font> and new     <font color="blue">applications</font> for our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">collaborate with</font>     academic  <font color="blue">institutions</font> and government research <font color="blue">laboratories</font> on product     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We have limited or <font color="blue">no control over</font> the resources that any     <font color="blue">collaborator</font>  may devote to our products</td>
    </tr>
    <tr>
      <td>Any of our present or future     <font color="blue">collaborator</font>s may not perform their <font color="blue">obligations</font> as expected</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">enter into</font> or maintain <font color="blue"><font color="blue">appropriate</font> collaboration <font color="blue">agreements</font></font>, or if any of     these events occur, we may not be able to develop some of our <font color="blue">new products</font>,     <font color="blue">which could</font> <font color="blue">materially</font> impede our ability to <font color="blue">generate revenue</font> or profits</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">strategic partners</font>, our <font color="blue">marketing efforts could</font> be impaired</td>
    </tr>
    <tr>
      <td>A substantial portion of our sales of <font color="blue">selected products consists</font> of sales to     <font color="blue">third parties</font> who incorporate our products in their systems</td>
    </tr>
    <tr>
      <td>We     have little or <font color="blue">no control over</font> their marketing and <font color="blue">sales <font color="blue">activities</font></font> or how     they use their resources</td>
    </tr>
    <tr>
      <td>Our present or future <font color="blue">strategic partners</font> may or     may  not purchase <font color="blue">sufficient quantities</font> of <font color="blue">products from us</font> or perform     <font color="blue"><font color="blue">appropriate</font> marketing</font> and <font color="blue">sales <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>In addition, if we are unable to     maintain our <font color="blue">relationship</font>s with <font color="blue">strategic partners</font>, our business may suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Failures </font>by our present or future <font color="blue">strategic partners</font>, or our <font color="blue">inability</font> to     maintain or <font color="blue">enter into</font> new arrangements with <font color="blue">strategic partners</font> for product     <font color="blue">distribution</font>, could <font color="blue">materially</font> impede the growth of our business and our     ability to <font color="blue">generate sufficient revenue</font> and profits</td>
    </tr>
    <tr>
      <td>If  we  are unable to make or complete future mergers, <font color="blue"><font color="blue">acquisition</font>s</font> or     <font color="blue"><font color="blue">strategic alliance</font>s</font> as a part of our <font color="blue">growth strategy</font> or integrate any such     mergers, <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue"><font color="blue">strategic alliance</font>s</font>, our business <font color="blue">development</font> may     suffer</td>
    </tr>
    <tr>
      <td>Our strategy includes <font color="blue"><font color="blue">potentially</font> expanding</font> our <font color="blue">technology</font> base through     selected  mergers,  <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue"><font color="blue">strategic alliance</font>s</font></td>
    </tr>
    <tr>
      <td>In 2005, our     indirect subsidiary, <font color="blue">Bruker AXS </font>GmbH, acquired Roentec AG, a broad-based     X-ray <font color="blue">analysis instrumentation company based</font> in Berlin, Germany, and our     direct       22     ______________________________________________________________________       subsidiary, Bruker AXS, acquired the <font color="blue">microanalysis</font> business of Princeton     Gamma-Tech Instruments, Inc, a <font color="blue">company located</font> in Rocky Hill, New Jersey</td>
    </tr>
    <tr>
      <td>The acquired <font color="blue">businesses</font> were combined to form a new group within <font color="blue">Bruker AXS </font>    that <font color="blue">will focus on</font> the X-ray <font color="blue">microanalysis</font> market, a market not <font color="blue">previously</font>     <font color="blue">addressed by</font> <font color="blue">Bruker AXS </font>In the <font color="blue">first quarter</font> of 2006, <font color="blue">Bruker AXS </font>GmbH     completed its <font color="blue">acquisition</font> of SOCABIM SAS, a privately-held Paris, France     <font color="blue">based company focused on advanced</font> X-ray <font color="blue">materials research</font> and analysis     software</td>
    </tr>
    <tr>
      <td>We may seek to continue to expand our <font color="blue">technology</font> base through mergers,     <font color="blue"><font color="blue">acquisition</font>s</font>  and  strategic  alliances</td>
    </tr>
    <tr>
      <td>If we fail to effect mergers,     <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue"><font color="blue">strategic alliance</font>s</font>, our <font color="blue">technology</font> base may not expand as     quickly and <font color="blue"><font color="blue">efficient</font>ly as possible</font></td>
    </tr>
    <tr>
      <td>Without <font color="blue">such complementary growth from</font>     selected mergers, <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue"><font color="blue">strategic alliance</font>s</font>, our ability to keep     up with the evolving needs of the market and to meet our <font color="blue">future performance</font>     <font color="blue">goals could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>However, we may not be able to find     <font color="blue">attractive candidates</font>, or <font color="blue">enter into</font> mergers, <font color="blue"><font color="blue">acquisition</font>s</font> or strategic     <font color="blue">alliances on terms</font> that are favorable to us, or <font color="blue"><font color="blue">successfully</font> integrate</font> the     <font color="blue">operations</font> of companies that we acquire</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may compete with</font>     other  companies  for  these merger, <font color="blue">acquisition</font> or <font color="blue">strategic alliance</font>     candidates, <font color="blue">which could</font> make such a <font color="blue">transaction</font> more expensive for us</td>
    </tr>
    <tr>
      <td>If we     are able to <font color="blue">successfully</font> identify and complete a merger, <font color="blue">acquisition</font> or     <font color="blue">strategic alliance</font>, it <font color="blue">could involve</font> a number of risks, including, among     others:       ·       the <font color="blue"><font color="blue">difficult</font>y</font> coordinating or <font color="blue">consolidating geographically separate</font>     <font color="blue">organizations</font> and <font color="blue">integrating</font> personnel with different business <font color="blue">backgrounds</font>     and <font color="blue">corporate cultures</font>;       ·       the <font color="blue"><font color="blue">difficult</font>y</font> of <font color="blue">integrating</font> <font color="blue">previously</font> autonomous departments in     <font color="blue">accounting</font>   and  finance,  sales  and  marketing,  <font color="blue">distribution</font>,  and     <font color="blue"><font color="blue">administrative</font> functions</font>, and expanding and <font color="blue">integrating</font> information and     <font color="blue">management</font> systems;       ·       the diversion of resources and <font color="blue">management</font> time;       ·       the <font color="blue">potential disruption</font> of our ongoing business; and       ·       the <font color="blue">potential <font color="blue">impairment</font></font> of <font color="blue"><font color="blue">relationship</font>s with customers as</font> a result     of changes in <font color="blue">management</font> or otherwise arising out of such <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue"><font color="blue">successfully</font> integrate</font> acquired <font color="blue">businesses</font>, we may not     be able to realize all of the <font color="blue">cost savings</font> and other benefits that we expect     to result from the <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>Goodwill and other <font color="blue">intangible assets</font> are subject to <font color="blue">impairment</font></td>
    </tr>
    <tr>
      <td>As a result of the merger of Bruker Daltonics and <font color="blue">Bruker AXS </font>in July 2003,     we <font color="blue">recorded goodwill</font> and other <font color="blue">intangible assets</font>, which must be <font color="blue">continually</font>     evaluated for <font color="blue">potential <font color="blue">impairment</font></font></td>
    </tr>
    <tr>
      <td>In addition, the recent <font color="blue"><font color="blue">acquisition</font>s</font> of     Roentec  AG  and  the  <font color="blue">microanalysis</font>  business of Princeton Gamma-Tech     Instruments, Inc</td>
    </tr>
    <tr>
      <td>resulted in <font color="blue"><font color="blue">additional</font> goodwill</font> and other intangible     assets</td>
    </tr>
    <tr>
      <td>We assess the <font color="blue">realizability</font> of the goodwill and other intangible     <font color="blue">assets annually as well as whenever events</font> or changes in <font color="blue">circumstances</font>     indicate that the <font color="blue">assets may</font> be impaired</td>
    </tr>
    <tr>
      <td>These events or <font color="blue">circumstances</font>     <font color="blue">generally</font> include operating losses or a <font color="blue">significant</font> decline in the earnings     <font color="blue">associated with</font> the business segment these <font color="blue"><font color="blue">acquisition</font>s</font> are reported within</td>
    </tr>
    <tr>
      <td>Our ability to realize the value of the <font color="blue">goodwill will depend on</font> the future     <font color="blue">cash flows</font> of the business segment in addition to how well we integrate the     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">risks applicable</font> to our <font color="blue"><font color="blue">life science</font> products</font>, our NBC     <font color="blue"><font color="blue">detection</font> products</font> are subject to a number of <font color="blue"><font color="blue">additional</font> risks</font>, including     lengthy product <font color="blue">development</font> and <font color="blue">contract negotiation periods</font> and certain     <font color="blue">risks inherent</font> in long-term government contracts</td>
    </tr>
    <tr>
      <td>Our NBC <font color="blue"><font color="blue">detection</font> products</font> are subject to many of the <font color="blue">same risks associated</font>     with  our  life  science  products,  including  <font color="blue">vulnerability</font> to rapid     <font color="blue">technological</font> change, dependence on mass <font color="blue">spectrometry</font> and other <font color="blue">technologies</font>     and substantial <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>In addition, our NBC <font color="blue"><font color="blue">detection</font> products</font> are     <font color="blue">generally</font> sold to <font color="blue">government agencies</font> under long-term contracts</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>contracts <font color="blue">generally</font> involve lengthy pre-contract       23     ______________________________________________________________________       <font color="blue">negotiations</font>  and  product  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may be required to devote     substantial working capital and other <font color="blue">resources prior</font> to obtaining product     orders</td>
    </tr>
    <tr>
      <td>As a result, we may incur substantial costs before we <font color="blue">potentially</font>     recognize revenue from these products</td>
    </tr>
    <tr>
      <td>Moreover, in return for larger,     longer-term contracts, our customers for these products often demand more     stringent <font color="blue">acceptance</font> criteria</td>
    </tr>
    <tr>
      <td>Their <font color="blue">criteria may also</font> cause delays in our     ability to recognize <font color="blue">revenue from sales</font> of these products</td>
    </tr>
    <tr>
      <td>Furthermore, we     may not be able to <font color="blue"><font color="blue">accurately</font> predict</font> in advance our costs to fulfill our     <font color="blue">obligations</font>  under these long-term contracts</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">accurately</font>     predict  our  costs, due to inflation or other factors, we <font color="blue">could incur</font>     <font color="blue"><font color="blue">significant</font> losses</font></td>
    </tr>
    <tr>
      <td>Any single long-term contract for our NBC <font color="blue">detection</font>     <font color="blue">products may represent</font> a material portion of our total business volume, and     the loss of any <font color="blue">such contract could</font> have a material adverse effect on our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to increase other business or to obtain     <font color="blue"><font color="blue">additional</font> government contracts</font>  could cause our revenue to decline</td>
    </tr>
    <tr>
      <td>Also,     the presence or absence of such contracts may cause substantial variation in     our results of <font color="blue">operations</font> between fiscal periods and, as a result, our     results of <font color="blue">operations</font> for any <font color="blue">given fiscal period may</font> not be predictive of     our results for <font color="blue">subsequent fiscal periods</font></td>
    </tr>
    <tr>
      <td>The resulting <font color="blue"><font color="blue">uncertainty</font> may</font>     have an <font color="blue"><font color="blue">adverse impact</font> on</font> our stock price</td>
    </tr>
    <tr>
      <td>If <font color="blue">general health care <font color="blue">spending patterns</font> decline</font>, our ability to generate     <font color="blue">revenue may suffer</font></td>
    </tr>
    <tr>
      <td>We are dependent, <font color="blue">both directly</font> and <font color="blue">indirectly</font>, upon general health care     <font color="blue">spending patterns</font>, <font color="blue">particularly</font> in the research and <font color="blue">development</font> budgets of     the  <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> industries, as well as upon the     <font color="blue">financial condition</font> of <font color="blue">various governments</font> and <font color="blue">government agencies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Since     </font>our inception, both we and our academic <font color="blue">collaborator</font>s and customers have     <font color="blue">benefited from various governmental contracts</font> and <font color="blue">research grants</font></td>
    </tr>
    <tr>
      <td><font color="blue">Whether     </font>we or our academic <font color="blue">collaborator</font>s <font color="blue">will continue</font> to be able to attract these     <font color="blue">grants depends</font> not only on the quality of our products, but also on general     <font color="blue">spending patterns</font> of public <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">proposed federal budget</font> for     fiscal year 2007 freezes spending for the National Institute of Health (NIH)     at dlra28dtta6 billion</td>
    </tr>
    <tr>
      <td>Such a freeze or a <font color="blue">potential decrease</font> in the level of     <font color="blue">governmental spending allocated</font> to scientific and <font color="blue">medical research which</font>     could <font color="blue">substantially</font> reduce or <font color="blue">even eliminate</font> our <font color="blue">grants as well as decrease</font>     demand for our <font color="blue">products from academic</font> and <font color="blue">medical research customers</font></td>
    </tr>
    <tr>
      <td>Any  reduction  in  the <font color="blue">capital resources</font> or <font color="blue">government funding</font> of our     <font color="blue"><font color="blue">customers could</font> reduce</font> our sales and impede our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our sales are <font color="blue">capital purchases by</font> our customers</td>
    </tr>
    <tr>
      <td>The <font color="blue">spending policies</font> of our <font color="blue">customers could</font> have a <font color="blue">significant</font> effect on     the demand for our products</td>
    </tr>
    <tr>
      <td>These policies are <font color="blue">based on</font> a wide variety of     factors, including the <font color="blue">resources available</font> to make purchases, the spending     <font color="blue">priorities among various types</font> of equipment, policies regarding spending     during  <font color="blue">recessionary periods</font> and changes in the <font color="blue">political climate</font></td>
    </tr>
    <tr>
      <td>Any     changes  in  <font color="blue">capital spending</font> or changes in the <font color="blue">capital budgets</font> of our     <font color="blue">customers could</font> <font color="blue">significant</font>ly reduce demand for our products</td>
    </tr>
    <tr>
      <td>The capital     resources of our bio<font color="blue">technology</font> and other <font color="blue">corporate customers may</font> be limited     by the <font color="blue">availability</font> of equity or <font color="blue">debt financing</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> decline in     research and <font color="blue">development</font> expenditures by our <font color="blue">life science</font> <font color="blue">customers could</font>     <font color="blue">significant</font>ly decrease our sales</td>
    </tr>
    <tr>
      <td>In addition, we make a substantial portion     of our sales to non-profit and <font color="blue">government entities which</font> are <font color="blue">dependent on</font>     <font color="blue">government support</font> for <font color="blue">scientific research</font></td>
    </tr>
    <tr>
      <td>Any decline in this support     <font color="blue">could decrease</font> the ability of these customers to purchase our products</td>
    </tr>
    <tr>
      <td>We are subject to existing and potential <font color="blue">additional</font> regulation, which can     <font color="blue">impose burdens on</font> our <font color="blue">operations</font> and narrow the markets for our products</td>
    </tr>
    <tr>
      <td>We are subject, <font color="blue">both directly</font> and <font color="blue">indirectly</font>, to the <font color="blue">adverse impact</font> of     existing and <font color="blue">potential future government regulation</font> of our <font color="blue">operations</font> and     markets</td>
    </tr>
    <tr>
      <td>For example, exportation of our products, <font color="blue">particularly</font> our NBC     <font color="blue"><font color="blue">detection</font> products</font>, is subject to <font color="blue">strict <font color="blue">regulatory</font> control</font> in a number of     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">satisfy export control criteria</font> or obtain     <font color="blue"><font color="blue">necessary</font> clearances could delay</font> or <font color="blue">prevent shipment</font>       24     ______________________________________________________________________       of products, <font color="blue">which could</font> <font color="blue">adversely</font> affect our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Moreover, the <font color="blue">life science</font>s industry, which is the market for our principal     products, has <font color="blue">historically</font> been heavily regulated</td>
    </tr>
    <tr>
      <td>There are, for example,     laws in several <font color="blue">jurisdictions</font> restricting research in <font color="blue">genetic engineering</font>,     which can operate to narrow our markets</td>
    </tr>
    <tr>
      <td>Given the evolving nature of this     industry, <font color="blue">legislative</font> bodies or <font color="blue">regulatory</font> <font color="blue">authorities</font> may adopt <font color="blue">additional</font>     <font color="blue">regulations</font> that <font color="blue">adversely</font> affect our market <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Additionally, if     ethical and other <font color="blue">concerns surrounding</font> the use of genetic information, gene     therapy or <font color="blue">genetically modified organisms become widespread</font>, we may have     less demand for our products</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">also directly <font color="blue">affected by</font></font> a     wide variety of government <font color="blue">regulations</font> applicable to business <font color="blue">enterprises</font>     <font color="blue">generally</font>  and to companies operating in the <font color="blue">life science</font>s industry in     particular</td>
    </tr>
    <tr>
      <td>Failure to comply with these <font color="blue">regulations</font> or obtain or maintain     <font color="blue">necessary</font> permits and licenses could result in a variety of fines or other     censures or an <font color="blue">interruption</font> in our business <font color="blue">operations</font> which may have a     negative  <font color="blue">impact on</font> our ability to <font color="blue">generate revenue</font>s</td>
    </tr>
    <tr>
      <td>In addition, our     compliance with existing <font color="blue">regulations</font>, such as the Sarbanes-Oxley Act of     2002,  may  have a material <font color="blue"><font color="blue">adverse impact</font> on</font> us</td>
    </tr>
    <tr>
      <td><font color="blue">Under Section </font>404 of     Sarbanes-Oxley, we are required to evaluate and determine the <font color="blue">effective</font>ness     of our <font color="blue"><font color="blue">internal control</font> structure</font> and procedures for financial reporting</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with this <font color="blue">legislation</font> may divert <font color="blue">management</font>’s attention and     resources and cause us to incur <font color="blue">significant</font> expense</td>
    </tr>
    <tr>
      <td>If we fail to maintain <font color="blue">effective</font> systems of <font color="blue"><font color="blue">internal control</font>s</font>, we may not be     able to <font color="blue">accurately</font> report our financial results</td>
    </tr>
    <tr>
      <td>As a result, current and     potential <font color="blue">stockholders</font> <font color="blue">could lose</font> confidence in our financial reporting,     which would harm our business and the <font color="blue">trading price</font> of our stock</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Effective </font> </font>internal  controls are <font color="blue">necessary</font> for us to <font color="blue">provide reliable</font>     financial reports</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">provide reliable</font> financial reports, our     business  and  operating  results could be harmed</td>
    </tr>
    <tr>
      <td>We have in the past     discovered, and may in the future discover, areas of our <font color="blue"><font color="blue">internal control</font>s</font>     that need <font color="blue">improvement</font></td>
    </tr>
    <tr>
      <td>For example, in our <font color="blue">Annual Report </font>on Form 10-K, for     the year ended <font color="blue">December </font>31, 2004, we identified and disclosed material     <font color="blue">weaknesses</font>  in  our  internal  <font color="blue">control <font color="blue">over financial</font></font> reporting at one     <font color="blue">significant</font>  subsidiary  whose  <font color="blue">operations</font> and <font color="blue">financial condition</font> are     <font color="blue">significant</font> to the Company’s <font color="blue">consolidated <font color="blue">financial statement</font>s</font></td>
    </tr>
    <tr>
      <td>In response     to these material <font color="blue">weaknesses</font> identified, we have taken steps to strengthen     our  internal  controls  over  financial reporting at this <font color="blue">significant</font>     subsidiary</td>
    </tr>
    <tr>
      <td>These steps have included the following:       ·       We evaluated and continue to evaluate the roles and <font color="blue">functions within</font>     the <font color="blue">significant</font> subsidiary’s <font color="blue">accounting</font> department and added <font color="blue">additional</font>     resources to support the <font color="blue">controls surrounding inventory valuation</font> and the     <font color="blue">financial statement</font> close process</td>
    </tr>
    <tr>
      <td><font color="blue">Temporary </font>staff had been used to perform     <font color="blue">additional</font> procedures while <font color="blue">management</font> evaluated resources and systems and     <font color="blue">permanent resources</font> were in place by the end of the <font color="blue">third quarter</font> of 2005</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Management </font> </font>believes that these <font color="blue">additional</font> resources together with the     existing <font color="blue">accounting</font> staff will enable proper financial reporting</td>
    </tr>
    <tr>
      <td>·        In addition to <font color="blue">augmenting</font> the Company’s <font color="blue">accounting</font> personnel,     <font color="blue">management</font> determined it was <font color="blue">necessary</font> to automate and <font color="blue">establish certain</font>     <font color="blue">preventative controls through</font> the <font color="blue">implementation</font> of a <font color="blue">fully integrated</font>     Materials Resource Planning (MRP) system</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>selected an MRP system     during the <font color="blue">third quarter</font> of 2005, and expects the <font color="blue">implementation</font> to be     completed during the <font color="blue">second quarter</font> of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that the above measures, when fully implemented, will     address the material <font color="blue">weaknesses</font> described in our <font color="blue">Annual Report </font>on Form 10-K,     for  the  year ended <font color="blue">December </font>31, 2004, in the near and long-term</td>
    </tr>
    <tr>
      <td>The     material  <font color="blue">weaknesses</font>  identified and disclosed in the <font color="blue">Annual Report </font>on     Form 10-K for the year ended <font color="blue">December </font>31, 2004 have <font color="blue">been remediated</font> in 2005     (See Item 9A, <font color="blue">Controls and Procedures</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">The Audit Committee </font>and <font color="blue">management</font>     <font color="blue">will continue</font> to monitor the <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">internal control</font>s</font> and     procedures on an ongoing basis and will take further action, as <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       As  part of our <font color="blue">ongoing monitoring</font> of <font color="blue">internal control</font> we <font color="blue">may discover</font>     material <font color="blue">weaknesses</font> or <font color="blue">significant</font> deficiencies in our <font color="blue">internal control</font> as     <font color="blue">defined under standards adopted by</font> the Public Company Accounting Oversight     Board, or PCAOB, that require <font color="blue">remediation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under the PCAOB </font>standards, a     “material  weakness”  is  a  <font color="blue">significant</font>  <font color="blue">deficiency</font> or <font color="blue">combination</font> of     <font color="blue">significant</font> deficiencies that results in more than a <font color="blue">remote likelihood</font> that     a material <font color="blue">misstatement</font> of the annual or interim <font color="blue">financial statement</font>s will     not  be prevented or detected</td>
    </tr>
    <tr>
      <td>A “<font color="blue">significant</font> <font color="blue">deficiency</font>” is a control     <font color="blue">deficiency</font> or <font color="blue">combination</font> of <font color="blue">control deficiencies</font>, that <font color="blue">adversely</font> affect a     company’s  ability  to initiate, authorize, record, process, or report     <font color="blue">external financial data reliably</font> in accordance with <font color="blue">generally</font> accepted     <font color="blue">accounting</font> principles such that there is a more than <font color="blue">remote likelihood</font> that     a <font color="blue">misstatement</font> of a company’s annual or interim <font color="blue">financial statement</font>s that is     more than inconsequential will not be prevented or detected</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>has concluded, and our independent registered public <font color="blue">accounting</font>     firm has attested, that the Company maintained <font color="blue">effective</font> <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting as of <font color="blue">December </font>31, 2005, <font color="blue">based on</font> criteria set     forth  by  the  Committee  of Sponsoring Organizations of the Treadway     Commission in Internal Control—Integrated Framework</td>
    </tr>
    <tr>
      <td>Any failure to maintain     <font color="blue">improvement</font>s in the <font color="blue">internal control</font> over our financial reporting could     cause us to fail to meet our reporting <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Our  success  depends  on our ability to operate <font color="blue">without infringing</font> or     <font color="blue">misappropriating</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>Our  commercial  <font color="blue">success depends on avoiding</font> the <font color="blue">infringement</font> of other     parties’ patents and <font color="blue"><font color="blue">proprietary</font> rights</font> as well as avoiding the breach of     any licenses relating to our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>Given that there may     be patents of which we are unaware, <font color="blue">particularly</font> in the US where patent     <font color="blue">applications</font> are <font color="blue">confidential</font>, avoidance of patent <font color="blue">infringement</font> may be     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Various third-parties hold patents which may relate to our     <font color="blue">technology</font>, and we may be found in the future to infringe these or other     patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font>, either with products we are     <font color="blue">currently marketing</font> or developing or with <font color="blue">new products</font> which we may develop     in the future</td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font> holding rights under a patent <font color="blue">successfully</font>     asserts an <font color="blue">infringement</font> claim with respect to any of our current or future     products, we may be <font color="blue">prevented from <font color="blue">manufacturing</font></font> or marketing our infringing     product in the country or <font color="blue">countries <font color="blue">covered by</font></font> the patent we infringe,     unless we can obtain a <font color="blue">license from</font> the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>We may not be able to     obtain a license on <font color="blue">commercially</font> reasonable terms, if at all, <font color="blue">especially</font> if     the <font color="blue">patent holder</font> is a <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>In addition, even if we can obtain a     license, it may be non-exclusive, which will permit others to practice the     same <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>We also may be required to pay substantial     damages to the <font color="blue">patent holder</font> in the event of an <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Under some     <font color="blue">circumstances</font> in the US, these damages could include damages equal to     triple the <font color="blue">actual damages</font> the <font color="blue">patent holder</font> incurs</td>
    </tr>
    <tr>
      <td>If we have supplied     <font color="blue"><font color="blue">infringing product</font>s</font> to <font color="blue">third parties</font> for <font color="blue">marketing by them</font> or <font color="blue">licensed third</font>     parties  to  <font color="blue">manufacture</font>, use or market <font color="blue"><font color="blue">infringing product</font>s</font>, we may be     obligated to indemnify these <font color="blue">third parties</font> for any damages they may be     required to pay to the <font color="blue">patent holder</font> and for any losses the <font color="blue">third parties</font>     <font color="blue">may sustain themselves as</font> the result of lost sales or <font color="blue">license payments</font> they     are required to make to the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>Any successful <font color="blue">infringement</font>     action  brought  against us may also <font color="blue">adversely</font> affect marketing of the     <font color="blue">infringing product</font> in other markets not <font color="blue">covered by</font> the <font color="blue">infringement</font> action,     as well as our marketing of other products <font color="blue">based on</font> similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Furthermore,  we  will  suffer  <font color="blue">adverse <font color="blue">consequences</font> from</font> a successful     <font color="blue">infringement</font> action against us even if the action is <font color="blue">subsequently reversed</font>     on appeal, nullified through another action or <font color="blue">resolved by settlement with</font>     the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>The damages or other <font color="blue">remedies awarded</font>, if any, may be     <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>As a result, any successful <font color="blue">infringement</font> action against us may     harm our business</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       If we are unable to <font color="blue">effective</font>ly protect our <font color="blue"><font color="blue">intellectual</font> property</font>, third     <font color="blue">parties may use</font> our <font color="blue">technology</font>, which <font color="blue">would impair</font> our ability to compete in     our markets</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued success will depend</font> in <font color="blue">significant</font> part on our ability to     obtain and maintain <font color="blue"><font color="blue">meaningful</font> <font color="blue">patent protection</font></font> for our <font color="blue">products throughout</font>     the  world</td>
    </tr>
    <tr>
      <td>We  rely  on patents to protect a <font color="blue">significant</font> part of our     <font color="blue"><font color="blue">intellectual</font> property</font> and to enhance our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>However, our     <font color="blue">presently pending</font> or future patent <font color="blue">applications</font> may not <font color="blue">issue as patents</font>,     and any patent <font color="blue">previously</font> issued to us may be challenged, invalidated, held     unenforceable or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Furthermore, the claims in patents which have     been  issued,  or  which may be issued to us in the future, may not be     <font color="blue">sufficiently</font>  broad  to prevent <font color="blue">third parties</font> from producing competing     products similar to our products</td>
    </tr>
    <tr>
      <td>In addition, the laws of <font color="blue">various foreign</font>     countries in which we <font color="blue">compete may</font> not protect our <font color="blue"><font color="blue">intellectual</font> property</font> to     the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Failure to obtain     adequate <font color="blue">patent protection</font> for our <font color="blue">proprietary</font> <font color="blue">technology</font> could <font color="blue">materially</font>     impair our ability to be <font color="blue">commercially</font> <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we <font color="blue">also rely on</font> the protection of trade     secrets, know-how and <font color="blue">confidential</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>To maintain     the  <font color="blue">confidential</font>ity  of <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information, we     <font color="blue">generally</font> seek to <font color="blue">enter into</font> <font color="blue">confidential</font>ity <font color="blue">agreements</font> with our employees,     <font color="blue">consultants</font> and <font color="blue">strategic partners</font> upon the <font color="blue">commencement</font> of a <font color="blue">relationship</font>     with us</td>
    </tr>
    <tr>
      <td>However, we may not obtain these <font color="blue">agreements</font> in all <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">unauthorized</font> use or <font color="blue">disclosure</font> of this information, these     <font color="blue">agreements</font>, even if obtained, may not provide <font color="blue">meaningful</font> protection for our     <font color="blue">trade secrets</font> or other <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, adequate     <font color="blue">remedies may</font> not exist in the event of <font color="blue">unauthorized</font> use or <font color="blue">disclosure</font> of     this  information</td>
    </tr>
    <tr>
      <td>The loss or exposure of our <font color="blue">trade secrets</font> and other     <font color="blue">proprietary</font> information <font color="blue">would impair</font> our <font color="blue">competitive</font> advantages and could     have a material <font color="blue">adverse affect on</font> our operating results, <font color="blue">financial condition</font>     and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">others may</font> have, or may in the     <font color="blue">future independently</font> develop, <font color="blue">substantially</font> similar or superior know-how and     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We may be involved in lawsuits to protect or enforce our patents that are     brought by us <font color="blue">which could</font> be expensive and time consuming</td>
    </tr>
    <tr>
      <td>In order to protect or enforce our <font color="blue">patent rights</font>, we may initiate patent     <font color="blue">litigation</font> against <font color="blue">third parties</font>, and we may be <font color="blue">similarly sued by others</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">may also become</font> subject to <font color="blue"><font color="blue">interference</font> <font color="blue">proceedings</font> conducted</font> in the patent     and <font color="blue">trademark offices</font> of <font color="blue">various countries</font> to determine the priority of     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">prosecution</font>, if <font color="blue">necessary</font>, of <font color="blue">intellectual</font>     property   suits,  <font color="blue">interference</font>  <font color="blue">proceedings</font>  and  related  legal  and     <font color="blue">administrative</font>  <font color="blue">proceedings</font>  is  costly  and diverts our technical and     <font color="blue">management</font> personnel from their <font color="blue">normal responsibilities</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse determination</font> of any <font color="blue">litigation</font> or defense     <font color="blue">proceedings</font>  could  put  our  patents  at risk of being invalidated or     <font color="blue">interpreted narrowly</font> and <font color="blue">could put</font> our patent <font color="blue">applications</font> at risk of not     issuing</td>
    </tr>
    <tr>
      <td>Furthermore, because of the substantial amount of <font color="blue">discovery</font> required in     connection with <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font>, there is a risk that some     of our <font color="blue">confidential</font> information could be compromised by <font color="blue">disclosure</font> during     this type of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, during the course of this kind of     <font color="blue">litigation</font>, there could be <font color="blue">public announcements</font> of the results of hearings,     motions or other interim <font color="blue">proceedings</font> or <font color="blue">development</font>s in the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">securities analysts</font> or investors perceive these results to be negative, it     could have a substantial negative effect on the <font color="blue">trading price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       We have agreed to share our name, portions of our <font color="blue"><font color="blue">intellectual</font> property</font>     rights and <font color="blue">distribution</font> channels with other <font color="blue">entities under common control</font>     <font color="blue">which could</font> result in the loss of our name and to lock in the price of     products we may sell to these <font color="blue">entities which may</font> not be the best price     available for these products</td>
    </tr>
    <tr>
      <td>We maintain a sharing agreement with 13 affiliated entities that requires us     to share portions of our <font color="blue"><font color="blue">intellectual</font> property</font> as it existed on <font color="blue">February </font>28,     2000 and our <font color="blue">distribution</font> channels with these <font color="blue">affiliated companies</font> and their     <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>We also share the Bruker name with many of these <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">could lose</font> the right to use the Bruker name if (a) we declare bankruptcy,     (b) we  interfere  with another party’s use of the name, (c) we take a     material action which <font color="blue">materially</font> detracts from the goodwill <font color="blue">associated with</font>     the name, or (d) we suffer a <font color="blue">major loss</font> of our reputation in our industry or     marketplace</td>
    </tr>
    <tr>
      <td>In addition, we have agreed to     maintain  the  price of some <font color="blue">products purchased from</font> and sold to these     <font color="blue">affiliates</font> for a period of up to <font color="blue">twelve years</font>, subject to <font color="blue">yearly adjustments</font>     equal to the increase in the <font color="blue">Consumer Price Index</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacture</font> and sale of <font color="blue">products could</font> lead to <font color="blue">product <font color="blue">liability</font></font> claims     for which we could have substantial <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of our products exposes us to <font color="blue">product <font color="blue">liability</font></font>     claims if any of our products cause injury or are <font color="blue">found otherwise unsuitable</font>     during <font color="blue">manufacturing</font>, marketing, sale or <font color="blue">customer use</font></td>
    </tr>
    <tr>
      <td>In particular, if one     of our NBC <font color="blue"><font color="blue">detection</font> products</font> malfunctions, this could lead to civilian or     <font color="blue">military casualties</font> in a time of unrest, exposing us to <font color="blue">increased potential</font>     for high-profile <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If our NBC <font color="blue"><font color="blue">detection</font> products</font> malfunction by     <font color="blue">generating</font> a false-positive to a <font color="blue">potential threat</font>, we could be exposed to     liabilities <font color="blue">associated with</font> actions taken that <font color="blue">otherwise would</font> not have been     required</td>
    </tr>
    <tr>
      <td>A successful <font color="blue">product <font color="blue">liability</font></font> claim <font color="blue">brought against us</font> in excess     of, or outside the coverage of, our <font color="blue">insurance coverage could</font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to maintain <font color="blue">product <font color="blue">liability</font></font> insurance on     acceptable terms, if at all, and <font color="blue">insurance may</font> not <font color="blue">provide adequate coverage</font>     <font color="blue">against potential liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Responding </font>to claims relating to improper handling, storage or disposal of     <font color="blue">hazardous</font> <font color="blue">chemicals</font> and <font color="blue">radioactive</font> and biological materials which we use     could be time consuming and costly</td>
    </tr>
    <tr>
      <td>We use controlled <font color="blue">hazardous</font> and <font color="blue">radioactive</font> materials in our business and     <font color="blue">generate wastes</font> that are regulated as <font color="blue">hazardous</font> wastes under <font color="blue">United States</font>     federal, and Massachusetts, California and Wisconsin state, <font color="blue">environmental</font>     and atomic energy <font color="blue">regulatory</font> laws and <font color="blue">under equivalent provisions</font> of law in     those <font color="blue">jurisdictions</font> in which our research and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> are     located</td>
    </tr>
    <tr>
      <td>Our use of these substances and materials is subject to stringent,     and <font color="blue">periodically</font> changing, regulation that can <font color="blue">impose costly compliance</font>     <font color="blue">obligations</font>  on  us  and  have  the  potential to <font color="blue">adversely</font> affect our     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>The risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or injury     from these <font color="blue">materials cannot</font> be <font color="blue">completely eliminated</font></td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> with     these  substances occurs, we could be held liable for any damages that     result, in addition to incurring clean-up costs and liabilities, which can     be substantial</td>
    </tr>
    <tr>
      <td>Additionally, an <font color="blue">accident</font> could damage our research and     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> resulting in delays and increased costs</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> various <font color="blue">key personnel</font> and must recruit <font color="blue">additional</font>     <font color="blue">qualified personnel</font> for a number of <font color="blue">management</font> positions</td>
    </tr>
    <tr>
      <td>Our success is highly <font color="blue">dependent on</font> the <font color="blue">continued services</font> of key <font color="blue">management</font>,     <font color="blue">particularly</font> our <font color="blue">chief executive officer</font>, <font color="blue">Frank H Laukien Ph</font></td>
    </tr>
    <tr>
      <td>D, as well as     technical and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">management</font> and other <font color="blue">employees may</font>     <font color="blue">voluntarily</font>  terminate their <font color="blue">employment with us at</font> any time upon short     notice</td>
    </tr>
    <tr>
      <td>The loss of the services of any member of our senior <font color="blue">management</font>,     technical  or  scientific staff may <font color="blue">significant</font>ly delay or prevent the     <font color="blue">achievement</font> of product <font color="blue">development</font> and other business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">success will also depend on</font> our ability to identify, recruit and retain     <font color="blue">additional</font>  qualified  scientific, technical and <font color="blue">managerial personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for <font color="blue">qualified personnel</font> is intense, <font color="blue">particularly</font> in the       28     ______________________________________________________________________       areas of information <font color="blue">technology</font>, engineering and science, and the process of     hiring suitably <font color="blue">qualified personnel</font> is <font color="blue">often lengthy</font></td>
    </tr>
    <tr>
      <td>If we are unable to     hire and retain a sufficient number of <font color="blue">qualified employees</font>, our ability to     conduct and expand our business could be <font color="blue">seriously reduced</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">chief executive officer</font> maintains <font color="blue">relationship</font>s with various <font color="blue">affiliates</font>     <font color="blue">which may impact</font> his <font color="blue">management</font> of us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">chief executive officer</font>, Frank H Laukien, Ph</td>
    </tr>
    <tr>
      <td>D, currently is, and has     been for over 10 years, a <font color="blue">management</font> officer and director of certain of our     <font color="blue">affiliates</font> and spends a considerable amount of time rendering services to     these <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although Dr</font></td>
    </tr>
    <tr>
      <td>Laukien spends the majority of his time     attending to our business, his <font color="blue">involvement with</font> these <font color="blue">affiliates</font> reduces the     time and attention he can devote to our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Laukien <font color="blue">beneficially</font>     owns directly or <font color="blue">indirectly</font> more than 10prca of our stock and more than 10prca of     the stock of several <font color="blue">affiliated companies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">collaborate with</font> some of these     <font color="blue">affiliates</font> in product <font color="blue">development</font>, and a portion of our <font color="blue">customer base also</font>     does business with these <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>We believe that all <font color="blue">agreements</font> with our     <font color="blue">affiliates</font> are at arm’s length commercial conditions and pricing</td>
    </tr>
    <tr>
      <td>Laukien’s <font color="blue">relationship</font> with and to these <font color="blue">affiliated companies</font> could     create an actual or perceived conflict of interest <font color="blue">which could</font> negatively     impact our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> or cash     flows</td>
    </tr>
    <tr>
      <td>We may not be able to maintain our sales and <font color="blue">service staff</font> to meet demand     for our products and services</td>
    </tr>
    <tr>
      <td>We  need to expand our <font color="blue">direct marketing</font> and <font color="blue">sales force as well as</font> our     service and <font color="blue">support staff</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future revenue</font> and <font color="blue">profitability</font> will depend     in  part  on our ability to maintain our team of marketing and service     personnel</td>
    </tr>
    <tr>
      <td>Because our products are technical in nature, we believe that our     marketing,  sales  and <font color="blue">support staff</font> must have scientific or technical     expertise and experience</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for employees with these skills is     intense</td>
    </tr>
    <tr>
      <td>We may not be able to continue to attract and retain sufficient     <font color="blue">qualified sales</font> and service people, and we may not be able to maintain and     develop an <font color="blue">efficient</font> and <font color="blue">effective</font> sales, marketing and support department</td>
    </tr>
    <tr>
      <td>If we fail to continue to attract or retain qualified people, then our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We plan <font color="blue">significant</font> growth, and there is a risk that we will not be able to     manage this growth</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend on</font> the expansion of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Effective </font>growth     <font color="blue">management</font> will place <font color="blue">increased demands on</font> our <font color="blue">management</font>, operational and     <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>To manage our growth, we must expand our <font color="blue">facilities</font>,     augment our operational, financial and <font color="blue">management</font> systems, and hire and     train <font color="blue">additional</font> <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>Our failure to manage this growth     <font color="blue">effective</font>ly could impair our ability to <font color="blue">generate revenue</font> or could cause our     expenses to increase more <font color="blue">rapidly than revenue</font>, resulting in operating     losses</td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our <font color="blue">revenue from <font color="blue">international</font> sales</font> and     are subject to the risks of doing business in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">sales account</font> and are expected to continue to account for a     <font color="blue">significant</font> portion of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> are,     and <font color="blue">will continue</font> to be, subject to a variety of risks <font color="blue">associated with</font>     conducting business <font color="blue"><font color="blue">international</font>ly</font>, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>These risks, which may <font color="blue">adversely</font> affect our ability to achieve and maintain     <font color="blue">profitability</font> and our ability to sell our products <font color="blue"><font color="blue">international</font>ly</font>, include:       ·       changes in <font color="blue">foreign currency <font color="blue">exchange rates</font></font>;       ·       changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>;       29     ______________________________________________________________________       ·       <font color="blue">legislation</font> and regulation, including tariffs, relating to the     import or export of high <font color="blue">technology</font> products;       ·       the imposition of <font color="blue">government controls</font>;       ·        political  and  <font color="blue">economic instability</font>, including <font color="blue">international</font>     <font color="blue">hostilities</font>, acts of terrorism and governmental restrictions, inflation,     trade <font color="blue">relationship</font>s and military and <font color="blue">political alliances</font>;       ·       costs and risks of <font color="blue">deploying systems</font> in <font color="blue">foreign countries</font>;       ·       <font color="blue">compliance with export laws</font> and controls in multiple <font color="blue">jurisdictions</font>       ·       limited <font color="blue"><font color="blue">intellectual</font> property</font> rights; and       ·       the burden of <font color="blue">complying with</font> a wide variety of <font color="blue">complex foreign laws</font>     and treaties, including unfavorable labor <font color="blue">regulations</font>, specifically those     applicable to our European <font color="blue">operations</font>, as well as US <font color="blue">laws affecting</font> the     <font color="blue">activities</font> of US <font color="blue">companies abroad</font></td>
    </tr>
    <tr>
      <td>While the impact of these factors is <font color="blue">difficult</font> to predict, any one or more     of these factors could <font color="blue">adversely</font> affect our <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>We  may  lose  money  when  we <font color="blue">exchange foreign currency</font> received from     <font color="blue">international</font> sales into US dollars</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our business is conducted in currencies other than     the US dollar, which is our reporting currency</td>
    </tr>
    <tr>
      <td>As a result, currency     <font color="blue"><font color="blue">fluctuation</font>s</font>  among  the US dollar and the currencies in which we do     business have caused and <font color="blue">will continue</font> to cause foreign currency <font color="blue">transaction</font>     gains and losses</td>
    </tr>
    <tr>
      <td>We recognize <font color="blue">foreign currency gains</font> or losses arising from     our <font color="blue">operations</font> in the <font color="blue">period incurred</font></td>
    </tr>
    <tr>
      <td>In addition, currency <font color="blue"><font color="blue">fluctuation</font>s</font>     could cause the price of our products to be more or less <font color="blue">competitive</font> than     our principal <font color="blue"><font color="blue">competitor</font>s</font>’ products</td>
    </tr>
    <tr>
      <td>Currency <font color="blue"><font color="blue">fluctuation</font>s</font> will increase or     decrease our <font color="blue">cost structure relative</font> to those of our <font color="blue"><font color="blue">competitor</font>s</font> <font color="blue">which could</font>     lessen the demand for our products and affect our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot predict</font> the effects of exchange rate <font color="blue"><font color="blue">fluctuation</font>s</font> upon our future     operating  results  because  of the number of <font color="blue">currencies involved</font>, the     <font color="blue">variability</font> of currency exposures and the <font color="blue">potential <font color="blue">volatility</font></font> of currency     <font color="blue">exchange rates</font></td>
    </tr>
    <tr>
      <td>Various <font color="blue">international</font> tax risks could <font color="blue">adversely</font> affect our earnings</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">international</font> tax risks</td>
    </tr>
    <tr>
      <td><font color="blue">Distributions </font>of earnings and     other payments received from our <font color="blue">subsidiaries</font> may be subject to withholding     taxes imposed by the countries where they are operating or are formed</td>
    </tr>
    <tr>
      <td>If     these <font color="blue">foreign countries</font> do not have <font color="blue"><font color="blue">income tax</font> treaties with</font> the United     States or the countries where our <font color="blue">subsidiaries</font> are <font color="blue">incorporated</font>, we could be     subject  to <font color="blue">high rates</font> of <font color="blue">withholding taxes on</font> these <font color="blue">distribution</font>s and     payments</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also</font> be subject to being <font color="blue">taxed twice on income</font> related to     <font color="blue">operations</font> in these non-treaty countries</td>
    </tr>
    <tr>
      <td>Because we are unable to reduce     the <font color="blue">taxable income</font> of one operating <font color="blue">company with losses incurred by</font> another     operating <font color="blue">company located</font> in another country, we may have a <font color="blue">higher foreign</font>     <font color="blue">effective</font> <font color="blue">income tax</font> rate than that of other companies in our industry</td>
    </tr>
    <tr>
      <td>The     amount of the credit that we may claim against our <font color="blue">United States</font> federal     <font color="blue">income tax</font> for foreign <font color="blue">income tax</font>es is subject to many <font color="blue">limitations which may</font>     <font color="blue">significant</font>ly restrict our ability to claim a credit for all of the foreign     taxes we pay</td>
    </tr>
    <tr>
      <td>Armed  <font color="blue">hostilities</font>  could  constrain  our  ability to conduct business     <font color="blue"><font color="blue">international</font>ly</font> and <font color="blue">could also</font> disrupt our <font color="blue">United States</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">current world unrest</font>, or the responses of the <font color="blue">United States</font>, may lead to     further acts of terrorism and <font color="blue">civil disturbances</font> in the <font color="blue">United States</font> or     elsewhere, which may further contribute to the <font color="blue">economic instability</font> in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>These attacks or <font color="blue">armed conflicts may affect</font> our physical     <font color="blue">facilities</font> or those of our suppliers or customers and could have an impact     on our domestic and <font color="blue">international</font> sales, our supply       30     ______________________________________________________________________       chain, our <font color="blue">production capability</font>, our <font color="blue">insurance premiums</font> or the ability to     <font color="blue">purchase insurance</font> and our ability to deliver our products to our customers</td>
    </tr>
    <tr>
      <td>The <font color="blue">consequences</font> of these risks are unpredictable, and their long-term     effect upon us is uncertain</td>
    </tr>
    <tr>
      <td>The <font color="blue">unpredictability</font> and <font color="blue">fluctuation</font> of our quarterly results may <font color="blue">adversely</font>     affect the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our revenues and results of <font color="blue">operations</font> have in the past and may in the     <font color="blue">future vary from quarter</font> to <font color="blue">quarter due</font> to a number of factors, many of     which are outside of our control and any of which may cause our stock price     to fluctuate</td>
    </tr>
    <tr>
      <td>The <font color="blue">primary factors</font> that <font color="blue">may affect us</font> include the following:       ·       the timing of sales of our products and services;       ·       the timing of recognizing revenue and <font color="blue">deferred revenue under</font> US     GAAP;       ·       changes in our <font color="blue">pricing policies</font> or the <font color="blue">pricing policies</font> of our     <font color="blue"><font color="blue">competitor</font>s</font>;       ·        increases  in  sales  and  marketing,  product <font color="blue">development</font> or     <font color="blue">administration expenses</font>;       ·       the mix of <font color="blue">services provided by us</font> and third-party contractors;       ·       our ability to attain and maintain <font color="blue">quality levels</font> for our products;     and       ·       costs related to <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">technology</font> or <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Historically, we have experienced a decrease in revenue in the <font color="blue">first quarter</font>     of <font color="blue">each fiscal year relative</font> to the prior fourth quarter, which we believe     is due to our customers’ budgeting cycles</td>
    </tr>
    <tr>
      <td>We <font color="blue">also traditionally</font> experience     <font color="blue">lower revenues</font> in the <font color="blue">third quarter</font> than throughout the rest of the year as     a  result  of  the  <font color="blue">European  </font><font color="blue">holiday schedule</font></td>
    </tr>
    <tr>
      <td>You should not rely on     quarter-to-quarter comparisons of our results of <font color="blue">operations</font> as an <font color="blue">indication</font>     of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>It is likely that in some <font color="blue">future quarters</font>, our     results  of  <font color="blue">operations</font> may be below the <font color="blue">expectations</font> of <font color="blue">public market</font>     analysts and investors</td>
    </tr>
    <tr>
      <td>In this event, the price of our <font color="blue">common stock</font> may     fall</td>
    </tr>
    <tr>
      <td>We face <font color="blue">potential <font color="blue">volatility</font></font> of our stock price</td>
    </tr>
    <tr>
      <td>There has only been a <font color="blue">public market</font> for our <font color="blue">common stock</font> since August 2000</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> may fluctuate <font color="blue">substantially</font> in response     to <font color="blue">various factors</font>, many of which are beyond our control, including:       ·       quarterly <font color="blue"><font color="blue">fluctuation</font>s</font> in results of <font color="blue">operations</font>, as described above;       ·       our ability to <font color="blue"><font color="blue">successfully</font> commercialize</font> our products;       ·       <font color="blue">technological</font> innovations or <font color="blue">new commercial products by us</font> or our     <font color="blue"><font color="blue">competitor</font>s</font>;       ·       <font color="blue">development</font>s concerning government <font color="blue">regulations</font> or <font color="blue"><font color="blue">proprietary</font> rights</font>     <font color="blue">which could</font> affect the <font color="blue">potential growth</font> of our markets;       ·       material changes in our <font color="blue">relationship</font>s with, or the viability of,     strategic business partners;       ·       <font color="blue">market reaction</font> to trends in revenues and expenses, <font color="blue">especially</font>     research and <font color="blue">development</font>;       ·       changes in earnings estimates <font color="blue">by analysts</font>;       ·       <font color="blue">volatility</font> and <font color="blue">uncertainty</font> in the <font color="blue">capital markets</font> in general;       ·       loss of <font color="blue">key personnel</font>;       ·       changes in <font color="blue">accounting</font> principles;       31     ______________________________________________________________________       ·       lack of <font color="blue">trading volume</font> in our stock;       ·       <font color="blue">fluctuation</font> within the <font color="blue">life science</font> sector;       ·       sales of <font color="blue">common stock</font> by existing <font color="blue">stockholders</font>, <font color="blue">particularly</font> large     <font color="blue">institutional investors</font> who cannot hold stock traded at less than dlra5 per     share; and       ·       economic and <font color="blue">political conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> may also be <font color="blue">affected by</font> our ability to     meet analysts’ <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Any failure to meet such <font color="blue">expectations</font>, even     slightly, could have an adverse effect on the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font>, the <font color="blue">NASDAQ National Market </font>and the     market for <font color="blue">life science</font> stocks in particular, has been and is subject to     <font color="blue">extreme price</font> and volume <font color="blue"><font color="blue">fluctuation</font>s</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font>     effect on the <font color="blue">market price</font>s of <font color="blue">securities issued by</font> many companies for     <font color="blue">reasons unrelated</font> to the operating performance of these companies</td>
    </tr>
    <tr>
      <td>In the     past, companies that have experienced <font color="blue">volatility</font> in the <font color="blue">market price</font> of     their  securities  have  been  the subjects of securities class action     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any such <font color="blue">litigation</font> instigated against us could result in     substantial costs and a diversion of <font color="blue">management</font>s’ attention and resources,     which  could  <font color="blue">significant</font>ly harm our business, <font color="blue">financial condition</font> and     operating results</td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">stock may impact</font> its <font color="blue">market price</font></td>
    </tr>
    <tr>
      <td>Sales of substantial numbers of shares of our <font color="blue">common stock</font> in the public     market, or the <font color="blue">perception</font> that <font color="blue">significant</font> sales are likely, could <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effect     that <font color="blue">market sales</font> of a large number of <font color="blue">shares would</font> have on the <font color="blue">market price</font>     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Existing <font color="blue">stockholders</font> have <font color="blue">significant</font> influence over us</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>1, 2006, our majority <font color="blue">stockholders</font> owned, in the aggregate,     <font color="blue">approximately</font>  59prca of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result, these     <font color="blue">stockholders</font> will be able to exercise substantial influence over all matters     requiring stockholder approval, including the election of <font color="blue">directors</font> and     approval of <font color="blue">significant</font> corporate <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>This could have the effect     of delaying or preventing a change in control of our company and will make     some <font color="blue">transaction</font>s <font color="blue">difficult</font> or impossible to accomplish without the support     of these <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies may</font> have <font color="blue"><font color="blue">difficult</font>y</font> acquiring us, even if doing so would     benefit our <font color="blue">stockholders</font>, due to <font color="blue">provisions under</font> our <font color="blue">corporate charter</font> and     bylaws, as well as <font color="blue">Delaware </font>law</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and our     bylaws, as well as <font color="blue">Delaware </font>law could make it more <font color="blue">difficult</font> for other     companies to acquire us, even if doing so <font color="blue">would benefit</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">bylaws contain</font> the     following provisions, among others, which may inhibit an <font color="blue">acquisition</font> of our     <font color="blue">company by</font> a <font color="blue">third party</font>:       ·       a <font color="blue">staggered board</font> of <font color="blue">directors</font>, where <font color="blue">stockholders</font> elect only a     minority of the <font color="blue">board each year</font>;       ·       <font color="blue">advance notification procedures</font> for matters to be brought before     <font color="blue">stockholder meetings</font>;       ·       a <font color="blue">limitation on</font> who may call <font color="blue">stockholder meetings</font>; and       ·       the ability of our board of <font color="blue">directors</font> to issue up to 5cmam000cmam000     shares of <font color="blue">preferred stock without</font> a <font color="blue">stockholder vote</font></td>
    </tr>
  </tbody>
</table>